Actively Recruiting
Jack Jumper Ant Venom Immunotherapy Long-term Effectiveness Investigation
Led by Murdoch Childrens Research Institute · Updated on 2026-03-31
100
Participants Needed
3
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Jack Jumper ant (JJA) venom allergy is a common Australian condition affecting up to three percent of the population and can cause severe allergic reactions to stings. This research aims to study the long-term effectiveness of venom immunotherapy (VIT) for JJA allergy, which is a known treatment to prevent severe reactions but lacks evidence regarding its lasting benefits and impact on quality of life. The trial is a phase 4, prospective, multicenter study conducted at three Australian hospitals. Participants who have completed a JJA VIT program lasting between 3 and less than 6 years, and who have been off treatment for at least 18 months but less than 5 years, will be invited to take part. They will undergo a supervised in-hospital JJA sting challenge and have blood samples taken to assess their venom tolerance. Questionnaires on quality of life, anxiety, depression, sting exposure, reactions, and attitudes toward adrenaline auto-injectors will be collected at enrollment, during the sting challenge, one month after, and annually for three years. Optional consent will be sought for blood serum biobanking and inclusion in a national allergy repository. Participants will be closely monitored during the sting challenge by clinicians assessing any systemic allergic reactions and their severity using the Brown Grading Criteria. The study will collect retrospective data from their previous treatment records and follow participants for three years to evaluate changes in reaction severity, quality of life, and use of auto-injectors. The total participation time includes the initial challenge and follow-up assessments, ensuring detailed safety monitoring and understanding of long-term outcomes.
CONDITIONS
Brief Title
Jack Jumper Ant Venom Immunotherapy Long-term Effectiveness Investigation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older who have completed a Jack Jumper Ant Venom Immunotherapy program at one of the three participating sites
- Completed a continuous JJA VIT program lasting between 3 and less than 6 years
- Have stopped JJA VIT treatment at least 18 months ago but less than 5 years ago
- Ability to provide informed consent
You will not qualify if you...
- Anyone younger than 18 years
- Adults who have not completed a continuous JJA VIT program lasting between 3 and less than 6 years
- Adults who stopped JJA VIT treatment less than 18 months ago or more than 5 years ago
- Anyone with a medical condition that increases risk during a sting challenge as judged by the investigator
- Individuals unable to understand study requirements or provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Completed prior to trial participation
Participants have previously completed Jack Jumper Ant Venom Immunotherapy lasting between 3 and less than 6 years and are now off treatment for at least 18 months but less than 5 years.
No visits during this trial stage
Duration - 1 day
Participants undergo an in-clinic Jack Jumper Ant sting challenge and complete questionnaires assessing quality of life, anxiety, depression, sting reaction history, and attitudes toward adrenaline autoinjector carriage. A blood sample is collected immediately prior to the sting challenge.
1 visit (in-person)
Duration - 3 years
Participants complete questionnaires on quality of life, anxiety, depression, sting reactions, and adrenaline autoinjector attitudes at 1 month post sting challenge and annually for 3 years. Optional blood collection for biobanking may also occur.
1 month post challenge visit and annual visits for 3 years
Trial Site Locations
Total: 3 locations
1
Royal Adelaide Hospital
Adelaide, South Australia, Australia, 5000
Actively Recruiting
2
Royal Hobart Hospital
Hobart, Tasmania, Australia, 7000
Actively Recruiting
3
Monash Medical Centre
Clayton, Victoria, Australia, 3168
Actively Recruiting
Research Team
N
National Allergy Centre of Excellence
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here